EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

OSU-T315 overcomes immunosuppression in triple-negative breast cancer by targeting the ILK/NF-κB signaling pathway to enhance immunotherapeutic efficacy

Yi Wang, Yuenong Qin, Chunyu Wu, Jiajing Chen, Yang Zhang, Yueqiang Chen, Xiaohong Xie, Xiufei Gao, Chenping Sun, Sheng Liu

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.113530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Yi Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Zhejiang 310…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Protein Serine-Threonine Kinases, Signal Transduction, NF-kappa B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Innovation Plan Of Shanghai Science and Technology Commission, Science and Technology Commission of Shanghai Municipality, Shanghai Shenkang Hospital Development Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple negative breast cancer (TNBC) is an aggressive and immunogenic subtype of breast cancer. The absence of biomarker has given immune checkpoint inhibitors (ICIs) a broad prospect in this type of breast cancer. The infiltration of regulatory T cells (Tregs) expressing transcription factor forkhead box P3 (Foxp3) in the tumor microenvironment (TME) is the key factor leading to ICIs resistance. Therefore, elimination of tumor antigen-specific Tregs may be an important aspect of improving ICIs efficacy. In this study, it based on the Gene Expression Omnibus and The Cancer Genome Atlas database, along with in vivo and in vitro experimental models, to verified that the high expression of integrin-linked kinase (ILK) in TNBC is the key differential factor leading to the high infiltration of Foxp3+-Tregs in the TME. Then, we selected ILK-specific inhibitor, OSU-T315, to intervene in vitro and vivo. Importantly, we found that OSU-T315 blocked the secretion of CCL17/CCL22 in tumor cells by inhibiting the ILK/NF-κB pathway, resulting in the apoptosis of Foxp3+-Tregs and decreased programmed cell death-1 (PD-1) expression. Therefore, our findings indicate a novel mechanism of OSU-T315 with potential therapeutic application in TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsProtein Serine-Threonine KinasesSignal TransductionNF-kappa BTumor MicroenvironmentT-Lymphocytes, RegulatoryHumansFemaleAnimalsCell Line, TumorMiceImmunotherapyMice, Inbred BALB CXenograft Model Antitumor AssaysMice, NudeForkhead Transcription FactorsScaffold Protein ILK

Stichwörter der Autor:innen

Integrin-linked kinaseOSU-T315Programmed cell death-1T regulatory cellsTriple negative breast cancer

Substanzen

Protein Serine-Threonine KinasesNF-kappa BForkhead Transcription FactorsScaffold Protein ILK

Autor:innen und Institutionen

  • Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Zhejiang 310000, China; Integrated Traditional Chinese and Western Medicine Breast…
  • Integrated Traditional Chinese and Western Medicine Breast Department, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China.
  • Thyroid and Breast Surgery Department, Affiliated Hospital to Shandong University of Traditional Chinese Medicine, Shandong 250000, China.
  • Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
  • Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Zhejiang 310000, China.
  • Integrated Traditional Chinese and Western Medicine Breast Department, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China. Electronic address: scplhyy@163.com.

Förderung

  • Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Shenkang Hospital Development Center

Zitieren

APA

Wang, Y., Qin, Y., Wu, C., Chen, J., Zhang, Y., Chen, Y., Xie, X., Gao, X., Sun, C., & Liu, S. (2024). OSU-T315 overcomes immunosuppression in triple-negative breast cancer by targeting the ILK/NF-κB signaling pathway to enhance immunotherapeutic efficacy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113530

Vancouver

Wang Y, Qin Y, Wu C, Chen J, Zhang Y, Chen Y, et al. OSU-T315 overcomes immunosuppression in triple-negative breast cancer by targeting the ILK/NF-κB signaling pathway to enhance immunotherapeutic efficacy. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113530

BibTeX
@article{Wang2024,
  author = {Wang, Yi and Qin, Yuenong and Wu, Chunyu and Chen, Jiajing and Zhang, Yang and Chen, Yueqiang and Xie, Xiaohong and Gao, Xiufei and Sun, Chenping and Liu, Sheng},
  title = {OSU-T315 overcomes immunosuppression in triple-negative breast cancer by targeting the ILK/NF-κB signaling pathway to enhance immunotherapeutic efficacy},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.113530}
}
Kostenlos starten →